Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale.

Angelika Janaszkiewicz, Ágota Tóth, Quentin Faucher, Hélène Arnion, Nicolas Védrenne, Chantal Barin-Le Guellec, Pierre Marquet, Florent Di Meo

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023;160():114342

PMID: 36739760

Abstract

The Organic Anion Transporter 1 is a membrane transporter known for its central role in drug elimination by the kidney. hOAT1 is an antiporter translocating substrate in exchange for a-ketoglutarate. The understanding of hOAT1 structure and function remains limited due to the absence of resolved structure of hOAT1. Benefiting from conserved structural and functional patterns shared with other Major Facilitator Superfamily transporters, the present study intended to investigate fragments of hOAT1 transport function and modulation of its activity in order to make a step forward the understanding of its transport cycle. μs-long molecular dynamics simulation of hOAT1 were carried out suggesting two plausible binding sites for a typical substrate, adefovir, in line with experimental observations. The well-known B-like motif binding site was observed in line with previous studies. However, we here propose a new inner binding cavity which is expected to be involved in substrate translocation event. Binding modes of hOAT1 co-substrate α-ketoglutarate were also investigated suggesting that it may bind to highly conserved intracellular motifs. We here hypothesise that α-ketoglutarate may disrupt the pseudo-symmetrical intracellular charge-relay system which in turn may participate to the destabilisation of OF conformation. Investigations regarding allosteric communications along hOAT1 also suggest that substrate binding event might modulate the dynamics of intracellular charge relay system, assisted by surrounding lipids as active partners. We here proposed a structural rationalisation of transport impairments observed for two single nucleotide polymorphisms, p.Arg50His and p.Arg454Gln suggesting that the present model may be used to transport dysfunctions arising from hOAT1 mutations.

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Address: Inserm U1248 Pharmacology & Transplantation, Univ. Limoges, 87000 Limoges, France.; Inserm U1248 Pharmacology & Transplantation, Univ. Limoges, 87000 Limoges, France; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utre-cht University, 3584 CG Utrecht, The Netherlands.; Inserm U1248 Pharmacology & Transplantation, Univ. Limoges, 87000 Limoges, France; CHU de Tours, 2 Boulevard Tonnellé, 37044 Tours, France.; Inserm U1248 Pharmacology & Transplantation, Univ. Limoges, 87000 Limoges, France; Department of Pharmacology and Toxicology, CHU Limoges, F-87000 Limoges, France.; Inserm U1248 Pharmacology & Transplantation, Univ. Limoges, 87000 Limoges, France. Electronic address: [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.